The decitabine brand and generics have a market value of over $91 million, while fosaprepitant has a brand market of approximately $279 million for the latest 12-month period.
Par is introducing an authorized generic of Merck Sharp & Dohme’s Noxafil (posaconazole) delayed-release tablets, and also plans to launch posaconazole 40mg/mL oral suspension in the coming months.